The increasing levels of complexity in the regulation of the pathway also call into play MDMX as a relevant modulator of p53 mono- or polyubiquitination by MDM2, which would alternatively cause its transcriptional inhibition and nuclear export versus proteolytic degradation, with relevant consequences on the biological outcome in normal and cancer cells (Wang and Jiang, 2012). This evidence concerns the gene TP53 and cancer.